Mutually exclusive. Prices sum to 100%.
Rule
This market resolves YES on the band containing Eli Lilly and Company's reported Mounjaro global revenue for Q2 2026, as disclosed in its Q2 2026 earnings release expected in early August 2026. Source: Eli Lilly investor relations and SEC EDGAR 10-Q filing. If Eli Lilly does not report Q2 2026 Mounjaro revenue by September 30, 2026, this market resolves NO.
Source: https://investor.lilly.com
Resolves by Aug 7, 2026.